Nkarta
NKTXNKTX · Stock Price
Historical price data
Overview
Nkarta is a clinical-stage biotech focused on developing engineered, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases and cancer. Its strategy centers on an allogeneic platform designed to overcome the manufacturing complexity and safety limitations of autologous cell therapies. The company has advanced its lead candidate, NKX019, into clinical trials for lupus nephritis and B-cell malignancies, supported by in-house GMP manufacturing capabilities and a strategic pivot emphasizing autoimmune indications.
Technology Platform
Proprietary platform for expanding and engineering allogeneic natural killer (NK) cells, incorporating chimeric antigen receptors (CARs) and membrane-bound IL-15 to create off-the-shelf, cryopreserved cell therapies.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| NKX019 + Fludarabine + Cyclophosphamide | Systemic Sclerosis | Phase 1/2 | |
| NKX019 + Fludarabine, Cyclophosphamide | Lupus Nephritis | Phase 1/2 | |
| NKX019 | Lymphoma, Non-Hodgkin | Phase 1 | |
| NKX101 - CAR NK cell therapy | Relapsed/Refractory AML | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Nkarta competes with autologous CAR-T leaders (e.g., BMS, Novartis) in autoimmune disease and a crowded field of allogeneic NK/T cell companies in oncology. Its key differentiation is its allogeneic NK platform focused on outpatient autoimmune therapy with a designed safety profile.
Company Timeline
Founded in South San Francisco, United States
Series A: $48.0M
IPO — $252.0M
Series B: $114.0M